Skip to Content

Press Releases

Press Releases

Mar 13 2019
Intec Pharma Announces Time Change for Presentation at Barclays Global Healthcare Conference
Presenting at 8:00 am Eastern time on March 14, 2019 JERUSALEM , March 13, 2019 /PRNewswire/ --   Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that the Company's presentation time at Barclays Global Healthcare Conference has been changed as follows.
Feb 28 2019
Intec Pharma to Participate at Four Investment Conferences in March
JERUSALEM , Feb. 28, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that Company management will participate at the following upcoming investment conferences in March.  Cowen 39th Annual Health Care Conference Date: March 11-13, 2019 Company
Feb 27 2019
Intec Pharma Reports Fourth Quarter and Year End 2018 Financial Results and Corporate Update
JERUSALEM , Feb. 27, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces financial results for the fourth quarter and year ended December 31, 2018 and provides a corporate update.  Highlights of the fourth quarter 2018 and recent weeks include:
Feb 19 2019
Intec Pharma Reports Positive Results from Pharmacokinetic Study of Accordion Pill™ Carbidopa/Levodopa 50/500 mg Dosed Three Times Daily
AP-CD/LD met primary endpoint of reducing plasma levodopa variability compared to standard oral CD/LD with statistical significance JERUSALEM , Feb. 19, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces the preliminary results from a pharmacokinetic
Jan 02 2019
Intec Pharma Advances Medical Cannabinoid Development Program With Dosing of First Patient in a Phase 1 Pharmacokinetic Study of Accordion Pill-THC
Pursuing medical cannabinoids for a variety of pain indications JERUSALEM , Jan. 2, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces the dosing of the first patient in a Phase 1 pharmacokinetic (PK) study of AP-THC, its proprietary Accordion
Dec 19 2018
Intec Pharma Publishes Letter to Shareholders
Reviews 2018 progress and provides outlook for 2019 JERUSALEM , Dec. 19, 2018 /PRNewswire/ --    Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that Jeffrey A. Meckler , Vice Chairman and Chief Executive Officer of Intec Pharma , has issued a Letter to Shareholders,
Dec 06 2018
Intec Pharma to Continue Development Collaboration to Next Phase
Accordion Pill for proprietary compound achieves in-vitro specifications Moving into clinical pharmacokinetic (PK) study in 2019 JERUSALEM , Dec. 6, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that the Accordion Pill™ developed for a
Nov 09 2018
Intec Pharma Reports Third Quarter 2018 Financial Results and Corporate Update
Completed enrollment in pivotal Phase 3 ACCORDANCE trial; on track for topline data in mid-2019 JERUSALEM , Nov. 9, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces financial results for the three and nine months ended September 30, 2018 and
Nov 06 2018
Intec Pharma to Participate in Upcoming November Investment Conferences
JERUSALEM , Nov. 6, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that Company management will participate at the following upcoming investment conferences in November.  H.C. Wainwright 2018 Annual Israel Conference Date: November 11, 2018
Oct 22 2018
Intec Pharma Completes Enrollment of Pivotal Phase 3 Clinical Trial of Accordion Pill™ Carbidopa/Levodopa for the Treatment of Advanced Parkinson's Disease Patients
On Track to Report Topline Data in Mid-2019 for Potential New Baseline Levodopa Treatment JERUSALEM , Oct. 22, 2018 /PRNewswire/ --  Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces the completion of patient enrollment in the Company's pivotal Phase 3 clinical trial
Displaying 21 - 30 of 101